Association of PAX2 and Other Gene Mutations with the Clinical Manifestations of Renal Coloboma Syndrome by 奥村 利矢 & Okumura Toshiya
RESEARCH ARTICLE
Association of PAX2 and Other Gene
Mutations with the Clinical Manifestations of
Renal Coloboma Syndrome
Toshiya Okumura1☯, Kengo Furuichi1,2☯*, Tomomi Higashide3, Mayumi Sakurai3, Shin-
ichi Hashimoto4, Yasuyuki Shinozaki4, Akinori Hara1, Yasunori Iwata4, Norihiko Sakai1,2,
Kazuhisa Sugiyama3, Shuichi Kaneko1, Takashi Wada4
1 Department of Disease Control, Institute of Medical, Pharmaceutical and Health Sciences, Faculty of
Medicine, Kanazawa University, Kanazawa, Japan, 2 Division of Blood Purification, Kanazawa University
Hospital, Kanazawa, Japan, 3 Departments of Ophthalmology and Visual Science, Institute of Medical,
Pharmaceutical and Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa, Japan,
4 Division of Nephrology, Department of Laboratory Medicine, Institute of Medical, Pharmaceutical and
Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa, Japan




Renal coloboma syndrome (RCS) is characterized by renal anomalies and optic nerve colo-
bomas. PAX2mutations contribute to RCS. However, approximately half of the patients
with RCS have no mutation in PAX2 gene.
Methods
To investigate the incidence and effects of mutations of PAX2 and 25 candidate genes,
patient genes were screened using next-generation sequence analysis, and candidate
mutations were confirmed using Sanger sequencing. The correlation between mutations
and clinical manifestation was evaluated.
Result
Thirty patients, including 26 patients (two families of five and two, 19 sporadic cases) with
RCS, and 4 optic nerve coloboma only control cases were evaluated in the present study.
Six PAX2mutations in 21 probands [28%; two in family cohorts (n = 5 and n = 2) and in 4 out
of 19 patients with sporadic disease] including four novel mutations were confirmed using
Sanger sequencing. Moreover, four other sequence variants (CHD7, SALL4, KIF26B, and
SIX4) were also confirmed, including a potentially pathogenic novel KIF26B mutation. Kid-
ney function and proteinuria were more severe in patients with PAX2mutations than in
those without the mutation. Moreover, the coloboma score was significantly higher in
patients with PAX2 gene mutations. Three out of five patients with PAX2mutations had
focal segmental glomerulosclerosis (FSGS) diagnosed from kidney biopsies.
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Conclusion
The results of this study identify several new mutations of PAX2, and sequence variants in
four additional genes, including a novel potentially pathogenic mutation in KIF26B, which
may play a role in the pathogenesis of RCS.
Introduction
Renal coloboma syndrome (RCS; papillorenal syndrome) is characterized by kidney hypoplasia
or dysplasia and abnormality of the optic nerve. Abnormal kidney structure and function vary
among patients. For example, some abnormalities are clinically silent but others include kidney
insufficiency and end-stage renal disease. Further, patients with RCS exhibit ocular abnormali-
ties. Developmental abnormalities of the optic nerve (ranging from mild optic disc dysplasia to
optic nerve aplasia), retina, choroid, and iris are included in coloboma [1]. Abnormal eye struc-
ture and function, such as serious retinal detachment and thin hypoplastic peripheral retinas,
also vary among patients [2]. Although the diagnosis of RCS is based on the morphological
examination of the kidney, ophthalmologic findings, and family history, the variations of clini-
cal manifestations make timely diagnosis difficult.
PAX2mutations represent one of the main genetic abnormalities of RCS [3, 4]. PAX2
encodes a transcription factor that mediates development and plays key roles in different stages
of the development of the kidneys, eyes, ears, and genital tract [5]. Studies of animals with
PAX2mutations show congenital loss of nephron number [2, 4–6].Approximately 170 cases
with PAX2 gene abnormalities have been reported in cases with RCS worldwide [7]. However,
around 50% cases of RCS have no abnormality in PAX2 gene[8].
PAX2 is a key transcriptional factor that functions in the regulation of a diverse range of
genes involved in kidney and eye development. A previous study using RNA-seq analysis fol-
lowing PAX2 siRNA knockdown identified 3135 transcripts differentially regulated by PAX2
[9]. PAX2-mediated gene expression is reportedly regulated by many transcriptional and intra-
cellular signaling factors including Wnt ligands, bone morphogenic proteins, fibroblast growth
factor, sonic hedgehog, RET/glial cell-derived neurotrophic factor, notch signaling pathways
[9], PAX2-binding proteins such as Hox11 and Eya1 [10], and epigenetic modulation of target
genes regulated by PTIP and the mixed-lineage leukemia (MLL) complex [11, 12]. Moreover,
kidney and eye development is regulated by a complex network of genes, including GDF11,
GDNF, FOXC1, SIX1, SALL1, PAX8, andWT1) [13]. Among them, we selected 25 candidate
genes. Therefore, we speculated mutations in our candidate genes, in addition to PAX2muta-
tions, contribute to RCS pathogenesis.
In the present study, we hypothesized that PAX2 and 25 candidate genes contribute to the
pathogenesis of RCS. Here we report the evaluation of 26 patients, including two family cohorts
(n = 5 and n = 2) and 19 patients with sporadic disease for mutations in PAX2 and 25 candidate
genes. We have detected four novel PAX2 mutations in 11 patients, and a potentially patho-
genic KIF26B mutation in one patient. Our results suggest that these mutations may contribute
to the pathogenesis of RCS.
Methods
Patients
Thirty patients, including two family cohorts (n = 5 and n = 2), 19 patients with sporadic RCS,
and 4 coloboma only control cases were evaluated in the present study. Although the diagnosis
of RCS is established according to clinical studies of the kidneys and eyes, there are no formal
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diagnostic criteria for RCS [14]. In the present study, we enrolled patients with kidney dysfunc-
tion, renal morphological abnormalities, or both. Optic nerve coloboma (dysplasia of the optic
nerve) was defined as a clearly demarcated bowl-shaped excavation of the optic disc, which is
typically decentered and deep. Slit-lamp examination, intraocular pressure measurement, fun-
dus examination, and photography as well as measurement of visual acuity were performed. In
addition to these clinical findings on the kidney and eyes, similar other syndromes were
excluded by clinical evaluation. Patients with CHARGE syndrome (coloboma, heart malforma-
tions, atresia choanae, retardation of growth and development, genital anomalies, and ear and
hearing abnormalities) were excluded according to the absence of the typical CHARGE syn-
drome findings of craniofacial abnormalities or cognitive difficulties. Patients with COACH
syndrome (cerebral vermis hypoplasia, oligophrenia, ataxia, optic nerve coloboma, hepatic
fibrosis) and Joubert syndrome were excluded according to the absence of the typical COACH
and Joubert syndrome findings of developmental disability, cerebellar hypoplasia, cerebellar
dysfunction, and hepatic dysfunction. We analyzed the sequences of PAX2 and 25 other genes
in 26 patients clinically diagnosed with RCS, and 4 optic nerve coloboma only patients as dis-
ease-negative controls.
Ethics statement
The Ethics Committee of the Kanazawa University Graduate School of Medicine approved the
study (Approval No. 169). All analyses in this study conformed to the ethical guidelines of the
1975 Declaration of Helsinki in its respective latest version. All individuals were>18 years of
age. Written informed consent was obtained from all participants.
Nucleotide sequence analysis
Screening of DNA sequences was conducted using an Ion Torrent PGM sequencer equipped
with the Ion 318 chip. We obtained sequences covering>90% of all genes, and the mean cover-
age was 97.7% (Table 1). Genomic positions of the mutations were determined using human
genome build 19 and the University of California, Santa Cruz genome annotation database
http://genome.ucsc.edu. The CLC Genomics Workbench was used to further process the
sequence alignments and genotyping data. Variants were filtered using data from dbSNP 142
and the 1000 Genomes Project.
PAX2 gene mutations were evaluated according to our published method[15]. Twelve
primer sets for each PAX2 exon were synthesized according to sequence information with
some modifications [16]. Amplified DNA fragments were purified and sequenced using a dye
terminator cycle sequencing kit (DYEnamic ET Terminator; GE Healthcare Bio-Sciences
Corp., Piscataway, NJ) and an automated DNA sequencer (ABI PRISM 310 DNA Sequencer;
Applied Biosystems, Foster City, CA). Candidate mutations of the 25 other genes were deter-
mined using Sanger sequencing with same primers used for the Ion Torrent PGM sequencer at
TaKaRa Dragon Genomics Center. Mutation Taster (http://www.mutationtaster.org) was used
to predict potential contributions of individual mutations to disease. Moreover, allele frequen-
cies were evaluated using the ExAc database (http://exac.broadinstitute.org).
Kidney biopsy specimens
Kidney biopsies were obtained from eight patients. For pathological diagnosis, a portion of
each kidney specimen was fixed with 10% phosphate-buffered formalin (pH 7.4), embedded in
paraffin, cut into 4-μm thick sections, and stained with hematoxylin and eosin, periodic acid-
Schiff’s reagent, periodic acid silver methenamine, and Mallory-Azan solutions.
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Scoring of optic disc coloboma
An experienced ophthalmologist (T. H.) reviewed photographs of the fundus of both eyes of
each patient to determine the presence of an optic disc coloboma and other abnormalities of
the fundus. The optic disc coloboma was scored according to a 5-point scale of 0 (normal) to 4
(severe) [8] as follows: 0 = normal; 1 = optic disc dysplasia, with an unusual pattern of retinal
vessels and cilioretinal arteries; 2 = optic disc pit associated with vascular abnormalities and a
cilioretinal artery; 3 = large coloboma involving the entire surface of the optic disc; 4 = large
coloboma of the optic disc and adjacent retina or morning-glory anomaly (with radial emer-
gence of the retinal vessels).
Statistical analysis
SPSS 19.0 and the StatView program were used for statistical analysis. Data are expressed as
the mean ± standard error (mean ± SEM). Statistical analyses were performed using the
Mann–Whitney U test; p< 0.05 indicated a statistically significant difference.
Table 1. DNA screening by next-generation sequencing.
Name Target (bp) Missed (bp) Covered (%)
1 WNT4 1111 88 92.1
2 SIX2 898 13 98.6
3 SIX1 877 0 100.0
4 SALL4 3206 0 100.0
5 SALL1 7266 87 98.8
6 NOTCH2 7987 139 98.3
7 FOXC1 1673 163 90.3
8 PAX8 1595 0 100.0
9 HNF1B 1971 0 100.0
10 EYA1 2125 0 100.0
11 HOX11 1041 14 98.7
12 RET 3756 8 99.8
13 PAX2 1602 0 100.0
14 KIF26B 6492 238 96.3
15 HESR1 1077 0 100.0
16 BMP7 1373 0 100.0
17 BMP4 1249 0 100.0
18 WT1 1780 76 95.7
19 WNT9A 1142 106 90.7
20 CHD7 9401 28 99.7
21 WNT9B 1118 81 92.8
22 LHX1 1276 84 93.4
23 GDNF 1076 6 99.4
24 NOTCH1 8042 106 98.7
25 JAG1 3943 10 99.8
26 SIX4 2379 65 97.3
Mean 2902.1 50.5 97.7
Gene mutations were screened using next-generation sequence analysis.
All genes were covered more than 90%, and the mean coverage was 97.7%.
doi:10.1371/journal.pone.0142843.t001
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Results
Detection of mutations in patients with RCS
Screening the sequences of PAX2 and 25 other genes identified 760 SNPs and 9 small indels.
Among them, 162 SNPs and 9 small indels were missense mutations. Moreover, 116 SNPs
were deleted by filtering using the dbSNP137 and the 1000 Genomes Project database. Of
these, 46 non-synonymous SNPs and 9 indels shared by the affected individuals were retained
in the analysis (Table 1).
Among candidate gene abnormalities, six PAX2mutations in 21 probands (28%; two in
family cohorts [n = 5 and n = 2] and in 4 out of 19 patients with sporadic disease), including
four novel mutations, were confirmed using Sanger sequencing (Table 1). Case 1–5 (a family)
had the novel mutationc.119-120delGC (ClinVar accession number; SCV000255937). The
novel heterozygous mutation ex2 c.187G>A (ClinVar accession number; SCV000255938) was
detected in exon 2 of Patient 9, which generates the missense mutation G63S (Fig 1). Patients
10 and 11 had the novel PAX2mutations ex2, c.57-58insGTGAACC (ClinVar accession num-
ber; SCV000255939) and ex3, c.224-225insAC (ClinVar accession number; SCV000255940),
respectively.
Fig 1. Mutations of PAX2. The paired domain of PAX family proteins (DNA binding domain) is well
conserved among PAX family members (A). Panel B shows a partial amino acid sequence of the paired
domain of PAX family proteins and PAX2 from different species. Yellow bars indicate sequences with 100%
identity with human PAX1–9 and four different species. Red and blue bars indicate mutations identified in the
present study and previous studies, respectively. Five mutation of PAX2were detected in exon 2. Three out
of five mutations were insertion or deletion mutation in exon 2 with frameshifts. These frameshifts created
new stop codons and thus generate nonsense mutations. Two other mutations were single nucleotide
mutations (ex2 c.187G>A, G63S and ex2 c.212G>C, R71T). These two mutations are shown in panels C.
The 3D-structure of the paired domain is shown in panel Ci. The 3D-structure highlighted by the square in
panel Ci is magnified in panel Cii. Changes in structure and electric polarity by G63S and R71Tmutations are
shown in panels Ciii to vi. Wild-type amino acids involved in DNA binding, glycine and arginine are shown in
red. These two non-polar amino acid residues were mutated to the polar amino acid residues, serine and
threonine, respectively. Blue and red highlighted amino acids in panels Cv and vi are hydrophobic and
hydrophilic, respectively.
doi:10.1371/journal.pone.0142843.g001
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Mutations of CHD7, SALL4, KIF26B, and SIX4 were confirmed using Sanger sequencing (S1
Fig). The SALL4 variant (ex3 c.541G>A) was detected in Patient 8, and Patient 12 had multiple
variants in CHD7 (ex1 c.1565G>T), KIF26B (ex12 c.55146-5167dell ACCTCGCCCCCCAGC
TCCGGGG) (ClinVar accession number; SCV000255941), and SIX4 (ex1 c.1778A>T). Muta-
tions were not detected in the other fourteen RCS cases without PAX2mutations and in four
patients with only optic nerve coloboma.
PAX2 DNA recognition site and mutations in PAX2 exon 2
The paired domain of PAX family proteins binds DNA and is well conserved among PAX pro-
teins of humans (Fig 1A). The yellow bars in Fig 1B indicate 100% conservation of the amino
acid sequences of PAX1 to 9 of humans and PAX2 of other species. Blue bars indicate known
mutations, and the red bars indicate mutations in this study. Six mutation of PAX2 were
detected in this study, and five of them were in exon 2. Three out of five mutations in exon 2
were insertion or deletion mutation with frameshifts. These frameshifts created new stop
codons and thus generate nonsense mutations. Two other mutations were single nucleotide
mutations (ex2 c.187G>A, G63S and ex2 c.212G>C, R71T) (Fig 1B). These mutations are
located within the three-dimensional structure of the paired domain of PAX shown in Fig 1C.
Blue and red indicate previously reported mutations and those discovered here, respectively.
Red contact DNA and original amino acids are glycine and arginine (Fig 1C, S1 Movie and S2
Movie). These two non-polar amino acid residues (hydrophobic) were mutated to the polar
(hydrophilic) amino acid residues serine and threonine, respectively. Mutation Taster was used
to predict the pathogenicity of mutations. Almost all the identified mutations in our cases were
found to have the potential to cause disease (Table 2).
Clinical manifestation of RCS with or without PAX2mutations
Among twenty-six patients clinically diagnosed with RCS, six probands (28%) had PAX2
mutations (Table 2). PAX2mutations were undetectable in the other fifteen patients (57.7%)
who were clinically diagnosed with RCS. Although 54.5% of patients with PAX2mutations
received hemodialysis, only 13.3% of those without PAX2mutations received dialysis or
received a kidney transplant (Table 3). Estimated GFR was lower in patients with PAX2muta-
tions (Fig 2A). Proteinuria was more severe in patients with PAX2mutations (Fig 2B).
Kidney biopsies were acquired from nine of twenty-six clinically diagnosed patients with
RCS. Five patients had PAX2mutations, and PAX2mutations were undetectable in four
patients. Three of five patients with PAX2mutations had FSGS (Table 3, Fig 2C), and the other
two had glomerulomegaly or non-IgA mesangial proliferative glomerulonephritis. However,
the four patients without PAX2mutations did not have FSGS, two had glomerulomegaly, and
one each had IgA nephropathy or minimal change nephrotic syndrome.
Thirteen and six patients had bilateral or monolateral typical ocular coloboma, respectively.
The coloboma scores were significantly higher in patients with PAX2mutations (Table 3, Fig
3). However, the degree of kidney dysfunction and coloboma varied, even among patients with
the same PAX2mutation.
Patients 8 and 12 had variants in other genes. Patient 8 had SALL4 variant. Patient 12 with
severe kidney dysfunction had three variants (KIF26B, CHD7, and SIX4) and subsequently
received a kidney transplant (Tables 2 and 3).
Familial cases with PAX2mutations
Patients 1–5 represented one family cohort with the same novel PAX2mutation ex2 c. 119-
120delGC (Table 2, Fig 4). Patients 1, 3, and 5 received hemodialysis. Although Patient 4 was
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the sister of Patients 3 and 5, who all had the same PAX2mutation, her kidney dysfunction was
mild (Cr 1.24 mg/dl). Patient 1 had a visual disability with some visual field defects. She and
her son (Patient 2, 18 years of age) had bilateral optic nerve coloboma, and they each had the
same PAX2mutation. The left eye of Patient 1 was the most severely affected (coloboma scores:
Patient 1, right eye score = 1, left eye score = 3; Patient 2, right eye score = 1, left eye score = 2
(Fig 4).
The second family cohort included Patient 6 and her mother, Patient 7. They had a hetero-
zygous PAX2mutation c.212G>C in exon 2 that creates the missense mutation R71T. Patient
6 previously reported as a case of acro-renal-ocular syndrome [17]. These patients received
Table 3. Clinical manifestation of renal coloboma syndromewith/without PAX2mutation.
Case Age Gender Coloboma Kidney
Rt Lt total Gross morphology Pathology Function
With PAX2 mutation 1 44 F 1 3 4 Normal ND HD
With PAX2 mutation 2 18 M 1 1 2 Malrotation Glomerulomegaly Cr 1.23
With PAX2 mutation 3 61 F 1 1 2 Hypoplasia/atrophy ND HD
With PAX2 mutation 4 59 F 3 4 7 Malrotation ND Cr 1.08
With PAX2 mutation 5 61 F 1 2 3 Hypoplasia/atrophy ND HD
With PAX2 mutation 6 34 F 3 3 6 Malrotation TIN HD
With PAX2 mutation 7 61 F 3 2 5 Hypoplasia/atrophy ND HD
With PAX2 mutation 8 28 F 1 3 4 ML, lt. double ureters FSGS Cr 1.47
With PAX2 mutation 9 37 F 3 1 4 Hypoplasia/atrophy Mes PGN Cr 2.20
With PAX2 mutation 10 14 M 3 3 6 Normal FSGS Cr 1.41
With PAX2 mutation 11 38 M 4 4 8 Hypoplasia/atrophy FSGS HD
Without PAX2 mutation 12 31 F 1 1 2 Rt. hypoplasia/atrophy ND Transplantation
Without PAX2 mutation 13 65 M 0 1 1 Malrotation IgA nephropaty Cr 1.27
Without PAX2 mutation 14 76 F 3 3 6 Malrotation Glomerulomegaly Cr 0.50
Without PAX2 mutation 15 27 M 1 1 2 Malrotation Glomerulomegaly Cr 1.80
Without PAX2 mutation 16 11 F 1 1 2 Malrotation ND Cr 0.50
Without PAX2 mutation 17 44 F 1 0 1 Malrotation ND Cr 0.60
Without PAX2 mutation 18 51 F 0 1 1 Hypoplasia/atrophy ND Cr 1.07
Without PAX2 mutation 19 65 M 1 0 1 Hypoplasia/atrophy ND Cr 1.97
Without PAX2 mutation 20 43 F 1 0 1 Hypoplasia/atrophy ND Cr 4.31
Without PAX2 mutation 21 37 M 1 0 1 Hypoplasia/atrophy MCNS Cr 2.26
Without PAX2 mutation 22 60 F 0 1 1 Malrotation ND Cr 0.69
Without PAX2 mutation 23 66 M 1 0 1 Rt. hypoplasia/atrophy ND Cr 1.57
Without PAX2 mutation 24 52 F 1 0 1 Rt. hypoplasia/atrophy ND CAPD
Without PAX2 mutation 25 47 M 1 1 2 Malrotation ND Cr 1.17
Without PAX2 mutation 26 63 M 1 1 2 Rt. hypoplasia/atrophy ND Cr 0.83
Coloboma only 27 29 F 1 1 2 Normal ND Cr 0.70
Coloboma only 28 30 F 1 0 1 Normal ND Cr 0.60
Coloboma only 29 73 F 1 1 2 Normal ND Cr 0.60
Coloboma only 30 65 F 1 0 1 Normal ND Cr 0.51
Optic nerve coloboma of each eye was scored 0 to 4 (Score 0, normal optic disc to score 4, severe c olobomma). Kidney abnormality of gross
morphology, pathology, and function are summarized. ND; not done, FSGS; focal segmental glomerulosclerosis, Mes PGN; mesangial proliferative
glomerulonephritis, MCNS; minimal change nephrotic syndrome.
doi:10.1371/journal.pone.0142843.t003
Gene Mutations in Renal Coloboma Syndrome
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hemodialysis and had very severe ocular coloboma (coloboma scores: Patient 6, right eye
score = 3, left eye score = 3; Patient 7, right eye score = 3, left eye score = 2).
Discussion
In the present study, we screened the nucleotide sequences of PAX2 and those of 25 other
genes and identified PAX2mutations, including four mutations that are novel, in 6 out of 21
probands who were clinically diagnosed with RCS (28%). Moreover, we detected four sequence
variants in other genes, including a novel KIF26B mutation.PAX2mutations manifest as clini-
cal abnormalities of the kidneys and eyes, and mutations in other genes may exert the same
effects. The most significant findings of the present study are as follows: 1. Mutations in genes
other than PAX2may contribute to the pathogenesis of RCS; 2. We present an analysis of a
series of kidney biopsies of patients with RCS; and 3. Factors other than PAX2mutations may
contribute to the progression of kidney and eye abnormalities in patients with RCS.
Of the 21 probands with RCS characterized here, 6 (28%) had PAX2 mutations, and two
further patients had sequence variants in other genes, including one patient with a novel
KIF26B mutation. Approximately 50% cases of RCS have no PAX2mutations[14]; however,
no other mutations are reported. We detected four non-PAX2 sequence variants in our cases of
Fig 2. Clinical manifestation of kidney in patients with PAX2mutations. PAX2mutations substantially
contribute to the renal manifestations of RCS. In patients without dialysis or kidney transplantation, estimated
GFR were lower in patients with PAX2mutations (A), and proteinuria was more severe in patients with PAX2
mutations (B). Histology of a renal biopsy specimen from Patient 8 is shown in panel C.A representative
segmental sclerosing lesion is observed at a glomerulus by PAS (i, ii) and PAM (iii) staining. Original
magnifications; panel I, ×100; planes ii and iii, ×400. Panel iv shows a representative image from
transmission electron microscopy at an original magnification of ×3,000. Foot process effacement is
observed without evidence of immune deposits. Scale bars represent 100 μm in light microscopy images and
5 μm in electron microscopy images. Values represent the mean ± SEM. *, p < 0.05 vs. “Coloboma only”.
“RCS with PAX2 mutations” indicates clinically diagnosed renal-coloboma syndrome cases with PAX2 gene
mutations (n = 5), “RCS without PAX2 mutations” indicates clinically diagnosed renal-coloboma syndrome
cases without PAX2 gene mutations (n = 13), and “Coloboma only” indicates cases with optic nerve
coloboma and no kidney abnormality (a disease control; n = 4).
doi:10.1371/journal.pone.0142843.g002
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RCS. Among them, we detected KIF26Bmutation that have not been reported, to our knowl-
edge, in patients with RCS. The allele frequency of CHD7, SIX4, and SALL4 sequence variants
were 0.04–0.2% and may therefore represent polymorphisms. Therefore, these sequence vari-
ants would not be considered to be pathogenic[18, 19]. In contrast, KIF26B, which encodes a
member of the kinesin family of motor proteins, exerts a major effect on development [20].
Thus, KIF26B-deficient mice exhibit neonatal lethality with impaired kidney development tow-
ing to the loss of cortical nephrogenic zone mesenchyme and the failure of ureteric buds to
invade and branch into the mesenchyme. To the best of our knowledge, the present study is the
first to detect a KIF26Bmutation in humans with kidney dysfunction. The novel KIF26B
sequence variant, which was a 22bp deletion affecting exon 12 of KIF26B, and was predicted to
cause a frameshift mutation prior to the termination of the coding region of KIF26B in exon
15, would be damaging to the protein. Because patient 12 with the KIF26B variant did not have
a PAX2 mutation, this mutation is potentially the causative mutation in this patient. Our
Fig 3. Optic nerve colobomawas severe in patients with PAX2mutations.Representative images of
coloboma scores 0–4 are shown in panel A. Score 0, normal optic disc; Score 1, optic disc dysplasia with an
unusual pattern of the retinal vessels and cilioretinal arteries; Score 2, optic disc pit associated with vascular
abnormalities and a cilioretinal artery; Score 3, large coloboma involving the entire surface of the optic disc;
Score 4, large coloboma of the optic disc and adjacent retina, or morning glory anomaly (with radial
emergence of the retinal vessels). The mean coloboma scores of each group are shown in panel B. The
coloboma scores (total, right and left eye) were significantly higher in patients with PAX2mutations. Values
represent the mean ± SEM. *, p < 0.05 vs. coloboma scores of patients without PAX2mutations. “RCS with
PAX2 mutations” indicates clinically diagnosed renal-coloboma syndrome cases with PAX2 gene mutations
(n = 11), “RCS without PAX2 mutations” indicates clinically diagnosed renal-coloboma syndrome cases
without PAX2 gene mutations (n = 15), and “Coloboma only” indicates cases with optic nerve coloboma and
no kidney abnormality (a disease control; n = 4).
doi:10.1371/journal.pone.0142843.g003
Gene Mutations in Renal Coloboma Syndrome
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patient with the KIF26Bmutation developed kidney dysfunction and eventually received a kid-
ney transplant. Further studies of renal coloboma syndrome that analyze exosome or whole
genome sequences are required to detect gene mutation in this syndrome and mutation in
other genes of patients with RCS.
Our analysis of kidney biopsies from nine of 26 patients with RCS reveal that five harbor-
PAX2mutations. Three of five patients with PAX2mutations, but not those without, exhibited
FSGS. Previous analyses of the biopsies of patients indicate that re-expression of PAX2 by
podocytes is an early marker of FSGS [21]. Moreover, proliferating parietal epithelial cells that
express PAX2 and cytokeratin may contribute to FSGS [22]. Moreover, a PAX2mutation con-
tributes to adult-onset FSGS, and 4% of patients with FSGS harbor the PAX2mutation [23].
Here we show that 60% of patients with PAX2mutations had FSGS, indicating that although
the mechanisms of FSGS progression are not defined, PAX2may play a critical role in disease
progression.
We report here two families with PAX2 mutations (Case1 to 5 and Case6, 7) in this manu-
script. Each member of one family (Case1 to 5) had one PAX2 mutation (c.119-120delGC),
and each member of another family (Case6 and 7) had the other PAX2 mutation (c.212G>C).
Although each family member had the same PAX2mutation, the extent of kidney dysfunction
differed significantly among them. Vesicoureteral reflux (VUR) is an important factor when
considering determinants of renal dysfunction of patients with RCS [24]. PAX2mutations con-
tribute to the kidney and urinary tract development, and participate in VUR. Minor VUR can
cause renal failure and kidney scarring over time. In addition to various pathological glomeru-
lar changes, the severity of VUR may explain the differences in kidney dysfunction between
subjects with the same PAX2mutation.
Ocular involvement is present in patients with PAX2mutations [25, 26], and bilateral optic
nerve coloboma is typically associated with RCS. Optic nerve or disc dysplasia,
Fig 4. Pedigree of the family with RCS with PAX2mutations. Pedigree of the family with RCS showing
classical autosomal dominant inheritance across three generations.☐, males;❍, females; ●, female patients
receiving hemodialysis. A diagonal line through a symbol means a patient is deceased.Ocular fundal images
of Patient 1 (B, C) indicate that she had ocular coloboma (coloboma scores: right eye = 1, left eye = 3). Cross-
sectional images of the optic disc acquired using optical coherence tomography (OCT) show deep
excavation in both eyes (C).
doi:10.1371/journal.pone.0142843.g004
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microphthalmia, morning glory anomaly, optic nerve cysts, scleral staphyloma, myopia, nys-
tagmus, and cataracts were observed as well [27, 28]. Our data reveal that optic nerve coloboma
was more severe in patients with PAX2mutations. However, the degree of optic nerve colo-
boma varied between patients or between each eye of an individual, although patients had the
same PAX2mutation. Moreover, a recent study reveals that even identical twins with PAX2
mutations show different eye and kidney abnormalities [29]. Consistent with the present data,
others suggest that point mutations within the coding region of PAX2may not represent the
only cause of RCS [14].These findings indicate that other factors may exert additive effects on
the progression of kidney and eye dysfunctions.
This study had some limitations. Parental studies are necessary to understand the contribution
of genetic mutations to clinical phenotypes. However, the approved protocol of the present study
did not include parents without the clinical manifestations of RCS. Therefore, we aim to include
parental studies in our future studies. Secondly, family bias may have been present in this study.
As RCS is very rare, we included as many cases as possible. Therefore, two families (of 5 and 2
cases, respectively) were included in this study. As there were significant differences in clinical
ocular and renal manifestations between individual family members with identical genemutations
[23, 30, 31], family bias may have affected the analysis conducted in the present study. Moreover,
the patient numbers in this study are very small, and that even just a small phenotypic bias can
sway the analysis one way or the other. Therefore conclusions from this study can only be very
tentative. Additional familial cases are required to adequately reduce this potential source of bias.
Our data indicate that PAX2mutation is a key abnormality in RCS and may make a major
contribution to the pathogenesis of kidney and eye abnormalities. However, other factors and
gene mutations may play a role, and further human and animal studies will be required to
define the mechanism of pathogenesis of RCS.
Supporting Information
S1 Fig. Mutations of KIF26B, CHD7, SIX4, and SALL4. To detect mutations associated with
renal coloboma syndrome (RCS), 26 patients with RCS and 4 patients with optic nerve colo-
boma only were screened using next-generation sequence analysis. Detected candidate muta-
tions were confirmed using Sanger sequencing. Mutation c.5146-5167delACCTCGCCCCCC
AGCTCCGGGG in KIF26B was detected in exon 12. Similarly, mutation c.1565 G>T in
CHD7 was detected in exon 1, mutation c.569 T>A in SIX4 was detected in exon 1, and muta-
tion c.2814 C>T in SALL4 was detected in exon 3.
(PPT)
S1 Movie. 3D-structure movie of the PAX2 paired domain binding to DNA. 3D-structure
images are shown in Fig 1 Ci-iv and Cv-vi, respectively. The 3D-structure of the paired domain
is shown in S1 Movie. Changes in structure by G63S and R71T mutations are shown. Wild-
type amino acids involved in DNA binding, glycine and arginine, are shown in red. These two
non-polar amino acid residues were mutated to the polar amino acid residues, serine and thre-
onine, respectively.
(MOV)
S2 Movie. 3D-electric polarity movie of the PAX2 paired domain binding to DNA. 3D-
structure images are shown in Fig 1 Ci-iv and Cv-vi, respectively. The 3D-structure of the
paired domain is shown in S2 Movie. Changes in electric polarity by G63S and R71T mutations
are shown. Amino acids highlighted in blue and red are hydrophobic and hydrophilic, respec-
tively.
(MOV)
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